INTRODUCTION: Recurrent bleeding in severe haemophilia B causes painful hemarthroses and reduces capacity for physical activity. Recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis results in low annualised bleeding rates, with the potential to improve patients' health-related quality of life (HRQoL). AIM: To present a post hoc analysis of data from B-LONG describing change over time in patient-reported outcomes associated with pain and physical activity. METHODS: Patients (≥12 years) who received weekly dose-adjusted or interval-adjusted rFIXFc prophylaxis and completed the Haemophilia-Specific QoL questionnaire for adolescents (Haemo-QoL) or adults (Haem-A-QoL) at baseline (BL) and end of study (EoS). Individual level changes i...
International audienceEQOFIX is a medicoeconomic study that analyzed the health-related quality of l...
Aims: Prophylaxis with standard-acting recombinant factor IX (rFIX) in hemophilia B patients require...
INTRODUCTION: Despite the well-documented benefits of prophylaxis, treatment burden is still a barri...
Background: Pain is a common symptom of hemophilia that may adversely affect patients’ quality of li...
BACKGROUND: Pain, a common symptom of hemophilia, begins early in life primarily due to joint bleedi...
Introduction: In 2017, all people with severe hemophilia B in Ireland switched to recombinant factor...
Abstract Introduction In 2017, all people with severe hemophilia B in Ireland switched to recombinan...
Haemophilia patients with inhibitors characteristically have impaired joint function and reduced hea...
From Crossref journal articles via Jisc Publications RouterHistory: ppub 2020-08-15, issued 2020-08-...
PubMedID: 23731246Patients with haemophilia A and inhibitors are at high risk for severe bleeding, p...
Patients with haemophilia A and inhibitors are at high risk for severe bleeding, progression of join...
Essentials: High-quality data are lacking on use of prophylaxis in adults with hemophilia and arthro...
Patients with haemophilia A and inhibitors are at high risk for severe bleeding, progression of join...
Introduction: In 2017, all people with severe haemophilia B (PWSHB) in Ireland switched from standar...
The Pro-FEIBA study reported health-related quality of life (HRQoL) improved following 6-month of Fa...
International audienceEQOFIX is a medicoeconomic study that analyzed the health-related quality of l...
Aims: Prophylaxis with standard-acting recombinant factor IX (rFIX) in hemophilia B patients require...
INTRODUCTION: Despite the well-documented benefits of prophylaxis, treatment burden is still a barri...
Background: Pain is a common symptom of hemophilia that may adversely affect patients’ quality of li...
BACKGROUND: Pain, a common symptom of hemophilia, begins early in life primarily due to joint bleedi...
Introduction: In 2017, all people with severe hemophilia B in Ireland switched to recombinant factor...
Abstract Introduction In 2017, all people with severe hemophilia B in Ireland switched to recombinan...
Haemophilia patients with inhibitors characteristically have impaired joint function and reduced hea...
From Crossref journal articles via Jisc Publications RouterHistory: ppub 2020-08-15, issued 2020-08-...
PubMedID: 23731246Patients with haemophilia A and inhibitors are at high risk for severe bleeding, p...
Patients with haemophilia A and inhibitors are at high risk for severe bleeding, progression of join...
Essentials: High-quality data are lacking on use of prophylaxis in adults with hemophilia and arthro...
Patients with haemophilia A and inhibitors are at high risk for severe bleeding, progression of join...
Introduction: In 2017, all people with severe haemophilia B (PWSHB) in Ireland switched from standar...
The Pro-FEIBA study reported health-related quality of life (HRQoL) improved following 6-month of Fa...
International audienceEQOFIX is a medicoeconomic study that analyzed the health-related quality of l...
Aims: Prophylaxis with standard-acting recombinant factor IX (rFIX) in hemophilia B patients require...
INTRODUCTION: Despite the well-documented benefits of prophylaxis, treatment burden is still a barri...